Takeda Pharmaceutical Company Limited Cash Flow-to-Debt Ratio
Takeda Pharmaceutical Company Limited cash flow-to-debt ratio. Takeda Pharmaceutical Company Limited (TKDA) has a Cash Flow-to-Debt Ratio of 0.05x as of December 2025, meaning its operating cash flow of €373.25 Billion could theoretically repay 0% of its total liabilities (€7.76 Trillion) in one year. Check TKDA cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Takeda Pharmaceutical Company Limited (2017–2025)
Cash flow-to-debt ratio of Takeda Pharmaceutical Company Limited from 2017 to 2025. Historical debt coverage capacity for Takeda Pharmaceutical Company Limited across 9 annual periods. Check earnings quality score of Takeda Pharmaceutical Company Limited to evaluate the quality of earnings relative to operating cash generation.
Takeda Pharmaceutical Company Limited Cash Flow-to-Debt Ratio by Year (2017–2025)
Takeda Pharmaceutical Company Limited cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for Takeda Pharmaceutical Company Limited. For the full cash flow conversion analysis, see Takeda Pharmaceutical Company Limited cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.14x | €1.06 Trillion | €7.31 Trillion | ▲ +58.1% |
| 2024 | 0.09x | €716.34 Billion | €7.83 Trillion | ▼ -28.9% |
| 2023 | 0.13x | €977.16 Billion | €7.60 Trillion | ▼ -14.2% |
| 2022 | 0.15x | €1.12 Trillion | €7.49 Trillion | ▲ +14.7% |
| 2021 | 0.13x | €1.01 Trillion | €7.74 Trillion | ▲ +57.9% |
| 2020 | 0.08x | €669.75 Billion | €8.09 Trillion | ▲ +119.4% |
| 2019 | 0.04x | €328.48 Billion | €8.71 Trillion | ▼ -79.1% |
| 2018 | 0.18x | €377.85 Billion | €2.09 Trillion | ▲ +66.6% |
| 2017 | 0.11x | €261.36 Billion | €2.41 Trillion | — |